Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.ABSTRACTSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC. We performed the forced degradation study of adalimumab, the first genetically engineered fully humanised immunoglobulin G1 monoclonal antibody, and evaluated tha possibilities of an advanced SEC column packed with sub-3 µm part...
Source: Acta Pharmaceutica - December 26, 2023 Category: Drugs & Pharmacology Authors: Jelena Kova čić Daniela Amid žić Klarić Nik ša Turk Ana Mornar Source Type: research
